Healthcare Industry News:  Animas  

Devices Mergers & Acquisitions

 News Release - January 19, 2006

Animas Corporation Stockholders to Vote on Johnson & Johnson Merger

Stockholders of Record on January 23, 2006 Eligible to Vote

WEST CHESTER, Pa.--(HSMN NewsFeed)--Jan. 19, 2006--Animas Corporation (Nasdaq:PUMP ) announced today that it will hold a Special Meeting of Stockholders on February 17, 2006, to vote on a proposal to approve the previously announced merger agreement between Animas, Johnson & Johnson and Emerald Merger Sub, Inc., a wholly owned subsidiary of Johnson & Johnson.

Stockholders of record as of January 23, 2006 will be entitled to vote and will be mailed a definitive proxy statement in connection with the meeting.

On December 16, 2005, Animas announced that it had entered into a definitive agreement with Johnson & Johnson whereby Emerald Merger Sub, Inc., a wholly owned subsidiary of Johnson & Johnson, would acquire Animas.

About Animas Corporation

Animas Corporation, a leading maker of insulin infusion pumps and related products, is dedicated to improving diabetes management and making insulin pump therapy easier for patients with insulin requiring diabetes and healthcare professionals through product innovation, exemplary customer support and superior customer education. For more information on Animas, visit or call Animas Corporation at 877-937-7867.

Safe Harbor

Statements in this press release or made by management from time to time regarding Animas Corporation that are not historical facts are forward-looking statements and are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. Any such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The following factors, among others, could cause Animas' actual results to differ materially from those described in a forward-looking statement: the failure to successfully commercialize the licensed or acquired technology; technical issues with the Company's products; any significant disruption with vendors; any failure to maintain profitability; technological breakthroughs in diabetes monitoring, treatment, or prevention that could render Animas' products obsolete; failure to comply with any FDA or foreign regulations; an inability to attract and retain personnel; competition; an inability to adequately protect Animas' intellectual property; disputes over intellectual property rights, including the risk of court-ordered injunctions prohibiting our manufacture or sale of a product following a finding of patent infringement; product liability lawsuits; and the failure to secure or retain third party insurance coverage or reduced reimbursement for Animas' products by third party payors. This list is intended to identify only certain of the principal factors that could cause actual results to differ. Readers are referred to the reports and documents filed from time to time by Animas Corporation with the Securities and Exchange Commission for a discussion of these and other important risk factors. Readers are cautioned not to place undue reliance on forward-looking statements, which are made as of the date of this press release. Animas Corporation undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or for any other reason.

Additional Information and Where to Find It:

This material is not a substitute for the proxy statement Animas Corporation will file with the Securities and Exchange Commission (SEC). You are urged to read the proxy statement when it becomes available, because it will contain important information. The proxy statement and other documents, which will be filed by Animas with the SEC, will be available free of charge at the SEC's website,, or by visiting Animas' website at

Animas and certain of its directors, executive officers and certain other members of its management may be deemed to be soliciting proxies from Animas' stockholders in connection with the proposed transaction. You may obtain a detailed list of names, affiliations and interests of Animas participants in the solicitation of proxies of Animas' stockholders by reading the proxy statement when it becomes available.

Source: Animas

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.